Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Randomized clinical trials with levosimendan.

Alexandre Mebazaa1, Damien Barraud, Stéphane Welschbillig

  • 1Department of Anesthesiology and Critical Care Medicine, Hôpital Lariboisière, Paris, France. alexandre.mebazaa@lrb.ap-hop-paris.fr

The American Journal of Cardiology
|September 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry.

European journal of heart failure·2021
Same author

Readmission following both cardiac and non-cardiac acute dyspnoea is associated with a striking risk of death.

ESC heart failure·2021
Same author

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.

American heart journal·2021
Same author

Rapid identification of bacteria from respiratory samples of patients hospitalized in intensive care units, with FilmArray Pneumonia Panel Plus.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Comparison of Circulating Immune Cells Profiles and Kinetics Between Coronavirus Disease 2019 and Bacterial Sepsis.

Critical care medicine·2021
Same author

A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients.

EClinicalMedicine·2021
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Levosimendan offers a dual mechanism for acute heart failure syndromes (AHFS). Clinical trials show it improves cardiac output, reduces PCWP, and enhances survival compared to dobutamine.

Area of Science:

  • Cardiology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Acute heart failure syndromes (AHFS) present significant treatment challenges.
  • Levosimendan's unique dual mechanism of action addresses unmet needs in AHFS management.

Purpose of the Study:

  • To evaluate the efficacy and safety of levosimendan in treating acute heart failure syndromes.
  • To compare levosimendan's effects with dobutamine and placebo in randomized controlled trials.

Main Methods:

  • Systematic review and meta-analysis of randomized, controlled clinical trials involving levosimendan.
  • Assessment of hemodynamic parameters (PCWP, cardiac output), clinical symptoms, and survival rates.

Main Results:

  • Levosimendan is well-tolerated and significantly reduces pulmonary capillary wedge pressure (PCWP) while increasing cardiac output.

Related Experiment Videos

  • Hemodynamic improvements and clinical symptom relief are more pronounced with levosimendan than dobutamine.
  • Levosimendan treatment demonstrated improved 6-month survival rates compared to dobutamine or placebo across three trials.

    • Conclusions:

    • Levosimendan shows promise as a first-line therapy for AHFS, potentially preventing myocardial injury.
    • Its favorable hemodynamic profile, symptom improvement, and survival benefits support its role in AHFS management.
    • Emerging data suggest benefits in acute myocardial ischemia, further supporting levosimendan's therapeutic potential.